WallStreetZenWallStreetZen

NYSEMKT: XXII
22nd Century Group Inc Stock

Overview
ForecastEarningsDividendOwnership
$1.06-0.03 (-2.75%)
Updated Feb 3, 2023
XXII Price
$1.06
Fair Value Price
N/A
Market Cap
$228.22M
52 Week Low
$0.82
52 Week High
$2.71
P/E
-4.08x
P/B
1.88x
P/S
3.83x
PEG
N/A
Dividend Yield
N/A
Revenue
$50.87M
Earnings
-$47.48M
Gross Margin
4.6%
Operating Margin
-97.92%
Profit Margin
-93.4%
Debt to Equity
0.17
Operating Cash Flow
-$37M
Beta
1.34
Next Earnings
Feb 27, 2023
Ex-Dividend
N/A
Next Dividend
N/A

XXII Overview

22nd Century Group, Inc., a plant biotechnology company, provides technology that allows to alter the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. The company offers SPECTRUM research cigarettes for use in independent clinical studies; and very low nicotine content (VLNC) tobacco cigarettes under the Moonlight and Moonlight Menthol brands. It is also involved in contract manufacturing business for third-party branded tobacco products. The company has a strategic research and development agreement with Keygene N.V. to develop hemp/cannabis plants for medical, therapeutic, and agricultural uses, as well as for other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Williamsville, New York.

Zen Score

–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how XXII scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

XXII is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
XXII is good value based on its book value relative to its share price (1.88x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.9x)
P/B vs Industry Valuation
XXII is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more XXII due diligence checks available for Premium users.

Be the first to know about important XXII news, forecast changes, insider trades & much more!

XXII News

Valuation

XXII price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-4.08x
Industry
18.24x
Market
15.09x

XXII price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.88x
Industry
1.9x
XXII is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

XXII's financial health

Profit margin

Revenue
$19.4M
Net Income
-$13.1M
Profit Margin
-67.6%
XXII's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
XXII's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$142.2M
Liabilities
$21.1M
Debt to equity
0.17
XXII's short-term assets ($64.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XXII's short-term assets ($64.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XXII's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
XXII's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$12.9M
Investing
-$19.3M
Financing
$31.9M
XXII's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

XXII vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
XXII$228.22M-2.75%-4.08x1.88x
BGXX$215.06M+19.81%N/A16.36x
KMDA$210.11M-1.47%-20.39x1.22x
ASRT$198.00M-1.20%7.19x1.47x
ZOM$274.39M-3.78%-20.00x1.02x
View Top Pharmaceutical Stocks

22nd Century Group Stock FAQ

What is 22nd Century Group's quote symbol?

NYSEMKT: XXII) 22nd Century Group trades on the NYSEMKT under the ticker symbol XXII. 22nd Century Group stock quotes can also be displayed as NYSEMKT: XXII.

If you're new to stock investing, here's how to buy 22nd Century Group stock.

What is the 52 week high and low for 22nd Century Group (NYSEMKT: XXII)?

(NYSEMKT: XXII) 22nd Century Group's 52-week high was $2.71, and its 52-week low was $0.82. It is currently -60.89% from its 52-week high and 29.27% from its 52-week low.

How much is 22nd Century Group stock worth today?

(NYSEMKT: XXII) 22nd Century Group currently has 215,301,603 outstanding shares. With 22nd Century Group stock trading at $1.06 per share, the total value of 22nd Century Group stock (market capitalization) is $228.22M.

22nd Century Group stock was originally listed at a price of $1.30 in Jan 26, 2011. If you had invested in 22nd Century Group stock at $1.30, your return over the last 12 years would have been -18.46%, for an annualized return of -1.69% (not including any dividends or dividend reinvestments).

How much is 22nd Century Group's stock price per share?

(NYSEMKT: XXII) 22nd Century Group stock price per share is $1.06 today (as of Feb 3, 2023).

What is 22nd Century Group's Market Cap?

(NYSEMKT: XXII) 22nd Century Group's market cap is $228.22M, as of Feb 6, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

22nd Century Group's market cap is calculated by multiplying XXII's current stock price of $1.06 by XXII's total outstanding shares of 215,301,603.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.